•  
  •  
 

Abstract

Inhalable drugs are widely used for treating lung diseases such as asthma, emphysema, and cystic fibrosis. The aerosol particles in these inhalable drugs may be charged electrostatically. The deposition of these inhaled therapeutic aerosol particles in the different regions of the lung depends on the particle aerodynamic diameter, electrostatic charge distribution, particulate number density, breathing rate, aerodynamics of the lung, ambient temperature, and relative humidity (RH). The primary mechanisms for lung deposition of inhaled particles are impaction, gravitational settling, diffusion, interception, and electrostatic attraction. To simulate lung deposition, electrostatically charged aerosol particles are introduced through a throat section into a glass bead lung model. The E-SPART analyzer was used to measure aerosol deposition as a function of the particle charge and size. Experiments were carried out to determine the increase in deposition efficiency as a function of the net charge-to-mass ratio (Q/M) of aerosol particles. Using a fairly monodisperse aerosol of 5.0 um count median aerodynamic diameter, it was found that the total deposition efficiency increased from 54% to 91% when Q/M increased from 0.5 to 9.67 |muC/g. The data show that enhanced delivery of the therapeutic aerosol in the lung can be achieved by controlling the electrostatic charge on the inhaled aerosol particles.

Share

COinS